 CAMBRIDGE, Mass., Nov. 08, 2021 GLOBE NEWSWIRE -- Werewolf Therapeutics, Inc. Nasdaq: HOWL, an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the bodys immune system for the treatment of cancer, today announced that management will present at the following investor conferences: 